KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Acquisitions & Divestments (2020 - 2025)

Neogenomics filings provide 6 years of Change in Acquisitions & Divestments readings, the most recent being $9.0 million for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 23.58% to $9.0 million in Q3 2025 year-over-year; TTM through Mar 2026 was $12.0 million, a 71.34% decrease, with the full-year FY2025 number at $20.1 million, down 62.79% from a year prior.
  • Change in Acquisitions & Divestments hit $9.0 million in Q3 2025 for Neogenomics, up from $3.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $40.4 million in Q1 2023 to a low of $3.0 million in Q2 2025.
  • Median Change in Acquisitions & Divestments over the past 5 years was $20.1 million (2024), compared with a mean of $19.3 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 673.94% in 2021 and later plummeted 85.29% in 2025.
  • Neogenomics' Change in Acquisitions & Divestments stood at $18.2 million in 2021, then skyrocketed by 48.64% to $27.1 million in 2022, then decreased by 10.52% to $24.3 million in 2023, then plummeted by 74.72% to $6.1 million in 2024, then soared by 46.77% to $9.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $9.0 million (Q3 2025), $3.0 million (Q2 2025), and $8.1 million (Q1 2025) per Business Quant data.